PepJunkie Home of the Peptonauts
More

Peptide Atlas · Peptide

Semax

Semax is the heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro, an analogue of the adrenocorticotropin fragment (4-10), reported after intranasal application to affect learning and to be neuroprotective.

What the evidence says

six tiers, never blended

emerging — human data exists, and it is thin or contested

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

  • created page created as 'Semax' · 2026-09-27 04:00 · somebody
  • kind set kind set to peptide: palette r1 · 2026-09-27 04:00 · somebody
  • fact added identity: PubChem CID 9811102: ACTH (4-7), Pro-Gly-Pro-, C37H51N9O10S, 813.9 g/mol. · 2026-09-27 04:00 · somebody
  • fact added identity: CAS registry number 80714-61-0. · 2026-09-27 04:00 · somebody
  • fact added identity: IUPAC name: (2S)-1-[2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoy · 2026-09-27 04:00 · somebody
  • fact added sequence: MEHFPGP · 2026-09-27 04:00 · somebody
  • fact added summary: Semax is the heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro, an analogue of the adrenocorticotropin fragment (4-10), reported · 2026-09-27 04:00 · somebody
  • fact added mechanism: A single application in rats raised hippocampal BDNF protein up to 1.4-fold and trkB phosphorylation 1.6-fold. · 2026-09-27 04:00 · somebody
  • fact added history: A 1997 review of fifteen years of its development describes it as one of the rare regulatory-peptide analogues to pass f · 2026-09-27 04:00 · somebody
  • citation added pmid 16996037 cited as preclinical: Semax regulates BDNF and trkB in the rat hippocampus · 2026-09-27 04:00 · somebody
  • citation added pmid 9173745 cited as emerging: Fifteen years of Semax design and study (Russian-language review) · 2026-09-27 04:00 · somebody

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.